3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
16
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Diffuse Intrinsic Pontine Glioma
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Astrocytoma
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
lutetium Lu 177 dotatate
5
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
pembrolizumab
2
olaparib
2
fludarabine
2
cabozantinib
2
X-Rays
2
Phantoms, Imaging
2
Cyclophosphamide
2
tivozanib
1
repotrectinib
1
pazopanib
1
fludarabine phosphate
1
entrectinib
1
belinostat
1
atezolizumab
1
aldesleukin
1
Yttrium-90
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
Octreotide
1
Nivolumab
1
Introns
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
ribociclib
×
30 days
×
Clear all
No trials found.